DEXIS to Showcase Cutting-Edge Innovations at IDS 2025
24.3.2025 09:00:00 CET | ACCESS Newswire | Press release
QUAKERTOWN, PENNSYLVANIA / ACCESS Newswire / March 24, 2025 / DEXIS, the global leader in dental imaging technologies, is excited to announce its participation in the International Dental Show (IDS) 2025 in Cologne, Germany.
The company will showcase new technologies within the DEXIS digital ecosystem, an AI-powered platform that connects each step of the digital workflow, from diagnosis to delivery. The ecosystem combines AI, 2D & 3D imaging, intraoral scanning, diagnostics, and treatment planning to create one integrated solution that streamlines processes and boosts productivity.
"We're excited to give IDS attendees the very first look at some of our new technologies," says DEXIS President, Robert Befidi. "All of our innovations are designed to improve patient interactions and make dental practices more effective and efficient. We're eager to put our products into the hands of dental professionals and demonstrate the capabilities of our new technologies."
Among these innovations are some exciting updates to the DEXIS intraoral scanning portfolio. Visitors will get an exclusive first look at the company's all-new intraoral scanner under development, Imprevo. With a sleek new design, fully rebuilt hardware, and AI-powered algorithm, Imprevo will become the new high-performance flagship of the DEXIS IOS portfolio.
IS ScanFlow, the software that powers the DEXIS intraoral scanner line, will preview its newest version, IS ScanFlow 2.0, featuring a new Smile Visualizer tool. The tool will allow dental professionals to show patients a realistic preview of their smile before and after treatments, helping them to visualize and better understand treatment recommendations.
DEXIS will also unveil updates to the ORTHOPANTOMOGRAPH™ OP 3D™ EX, which will soon include cephalometric imaging capabilities. The new ceph modality, which features the company's patented ORTHOceph™ Plus design, will provide necessary protocols such as lateral and pediatric lateral projections, posterior-anterior projections and carpus imaging* - all with fast scan times and at a limited dose.
Additionally, the DEXIS 3D imaging portfolio will introduce an Automatic Dose Control feature for the ORTHOPANTOMOGRAPH™ OP 3D™ LX. The feature will measure patients' anatomy and automatically set exposure levels for optimal image quality and dose. Early adopters have reported positive feedback:
"The new Automatic Dose Control is one of the few things in life I don't have to question," says Dr. Katya Archambault of San Diego Health Center. "It offers both better and more consistent image quality. I could never argue with the results."
Also being showcased are new features within DTX Studio™ Clinic, the core software of the DEXIS digital ecosystem. Known for its comprehensive integration of all modalities of patient data, DTX Studio Clinic streamlines diagnostics, patient education, treatment planning, and surgical guide generation.
The software's new features include a suite of tools designed to streamline the implant treatment planning process. Users can now plan an implant treatment and generate an automated surgical template chairside in under 3 minutes. Additionally, the software introduces an Assisted Implant Planning module that automates initial implant positioning, and a Face Scan tool that integrates facial scans with 3D X-rays, further enhancing the planning process.
Attendees will also get the chance to preview new innovations, set to be released in future updates of DTX Studio Clinic. Among these innovations is a new, AI-driven endodontic capability, that will provide 3D visualizations of root canals, enhancing diagnostic accuracy and treatment efficiency. Additionally, updates to the focus areas detection tool will be showcased, enhancing the visualization of teeth in intraoral X-rays and detecting eight additional dental findings.
DTX Studio Clinic will also introduce a new Cloud-based solution that will allow clinicians to connect their practices and consolidate data in one place. This feature is designed to enhance collaboration and streamline workflows, ultimately improving practice efficiency and patient outcomes. These advancements showcase the future of dental technology, making DTX Studio Clinic an integral part of modern dentistry.
DEXIS invites all IDS attendees to visit Hall 11.2 K050 L069 to experience the innovations that DEXIS has to offer. Their team of experts will be ready to provide demonstrations and answer questions.
With more than 165,000 solutions in use around the world, DEXIS continues to set the standard for quality and reliability in dental imaging. For more information about DEXIS and its participation in IDS, please visit DEXIS @ IDS 2025.
About DEXIS
DEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit DEXIS.com.
About Envista
Envista Holdings Corporation is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
DXIS01006/Rev00
*Carpus is an optional imaging program
Contact Information
Maria Penaloza
Media & Content Strategy Manager
mariap@accessnewswire.com
Michelle Cabral
Senior Marketing Director, DEXIS
michelle.cabral@envistaco.com
SOURCE: Envista
View the original press release on ACCESS Newswire
Envista
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release
Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we
Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release
Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging
Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release
Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm
AI Trading Bots Revolutionise Stock, Gold, and Forex Trading: Funds Coin Leads the Move with Guaranteed Profit Option Strategy19.5.2026 14:00:00 CEST | Press release
DENVER, CO / ACCESS Newswire / May 19, 2026 / Forex has always been the world's largest digital financial market in 2026. Now it has become entirely a 24-hour, data-saturated environment. According to the Bank for International Settlements, global OTC foreign exchange turnover reached $9.6 trillion per day in April 2025. This means the foreign exchange turnover was up 28% from 2022. This is a figure that underscores just how deeply connected forex is to global liquidity, risk management, and capital flows. Inside that volume, the competition has intensified dramatically. In 2026, retail traders are no longer competing mainly against other individuals; they are competing against automated systems, and AI-assisted execution engines like Funds Coin. The platform operates across stocks, forex, and financial markets simultaneously. Manual trading, in this environment, is not just inefficient. It is structurally outpaced. Why AI Bots Are Taking Over Forex The following table is provided for
Northfield's Flagship Investment Juno Corp. Discovers Heavy Rare Earth Magnet Metals at Vespa19.5.2026 13:01:00 CEST | Press release
Broadens Juno's Polymetallic Critical Minerals System in Ontario's Ring of Fire TORONTO, ON / ACCESS Newswire / May 19, 2026 / Northfield Capital Corporation ("Northfield" or the "Company") (TSXV:NFD.A) is pleased to comment on the announcement made today by Juno Corp. ("Juno") regarding the discovery of heavy rare earth element ("HREE") mineralization, including the magnet metals neodymium, praseodymium, dysprosium and terbium, within Juno's Vespa critical minerals system in Ontario's Ring of Fire (the "Juno Announcement"). For the full text of the Juno Announcement, including the technical disclosure relating to drill hole VES-26-025 and the associated assay results, please refer to Juno's press release dated May 19, 2026, available at www.junocorp.com. Northfield holds an approximately 35% equity interest in Juno, making Juno one of the most significant investments in Northfield's portfolio. The discovery disclosed in the Juno Announcement broadens the polymetallic critical minerals
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom